BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
PRAX upcoming catalysts
Praxis Precision Medicines: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 0 FDA event(s). Subscribe to PRAX (.ics).
Upcoming FDA decision events
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-12 est. | P3 | Praxis Precision Medicines PRAX | NCT07010471 A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | Developmental and Epileptic Encephalopathy 1 | active not recruiting | 160 |
| 2026-12 est. | P3 | Praxis Precision Medicines PRAX | NCT07019922 A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | Epileptic Encephalopathy; SCN2A Encephalopathy | recruiting | 40 |
| 2027-01 est. | P3 | Praxis Precision Medicines PRAX | NCT07505004 Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | Focal Epilepsy | active not recruiting | 300 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|
| No FDA decision events in this window. |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-05-14 | P2/P3 | Praxis Precision Medicines PRAX | NCT06999902 Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) | Focal Seizure | completed | 255 |
| 2026-04-01 | P1/P2 | Praxis Precision Medicines PRAX | NCT05737784 A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy | SCN2A-DEE; Epilepsy | active not recruiting | 60 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.